Evidence map›Paper›PMID 42935764›Full record

ReviewFrontiers in immunology2026

Histotripsy in tumor therapy: advances in non-thermal mechanical ablation, immune modulation, and clinical translation.

Yangyang Ma, Xinan Long, Jiangpeng Cheng, Lizhi Niu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yangyang MaCentral Laboratory, Guangzhou Fuda Cancer Hospital, Guangzhou, China.
Xinan LongDepartment of Oncology, Guangzhou Fuda Cancer Hospital, Guangzhou, China.
Jiangpeng ChengDepartment of Oncology, Guangzhou Fuda Cancer Hospital, Guangzhou, China.
Lizhi NiuDepartment of Oncology, Guangzhou Fuda Cancer Hospital, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histotripsy is an emerging non-invasive focused-ultrasound technology that mechanically disrupts tissue through controlled bubble activity rather than sustained thermal coagulation. This review distinguishes shock-scattering cavitational histotripsy, intrinsic threshold histotripsy, and boiling histotripsy and relates their pulse regimes, bubble dynamics, tissue effects, monitoring strategies, and evidence maturity. Mechanical fractionation can expose tumor antigens and damage-associated molecular patterns, but immune outcomes vary by submodality, dose, tumor model, treated fraction, and sampling time; no standardized head-to-head evidence establishes a superior immunological approach. Early prospective liver studies demonstrate high technical feasibility and encouraging local control, whereas post-market cohorts also reveal targeting limitations and uncommon but clinically important vascular, thrombotic, and renal complications. Pancreatic investigation remains ongoing, while the renal CAIN study is completed with registry results and a peer-reviewed first-patient report. A clinically useful dosimetry framework should connect delivered acoustic parameters with

Indexed as

High-Intensity Focused Ultrasound AblationImmunomodulationNeoplasmsAnimalsHumansTranslational Research, Biomedicalboiling histotripsycavitationclinical translationfocused ultrasoundhistotripsyimmunogenic cell deathmicrotripsytumor ablation

Identifiers

PMID42935764
PMCPMC13696946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.